Stockwatch: Expirations, the Euro and Q2 Expectations
This article was originally published in Scrip
Executive Summary
With a handful of pharmaceutical companies and fewer biotechnology companies reporting second quarter financial results this last week, the stage has already been set for the crucial issues that should permeate through this reporting season.